MADIT poses ethical dilemma for implantable cardioverter defibrillator (ICD) panel
This article was originally published in Clinica
Executive Summary
The deadlock over prophylactic use of ICDs in the US could be broken by publication of the MADIT trial data in a peer review journal. Although the results were presented in full at the North American Society of Pacing and Electrophysiology meeting in May, they are not technically in the public domain as far as the FDA is concerned. The study has been submitted but a publication date has not been announced.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.